Institute Of Hematology & Blood Diseases Hospital, China

This early-phase study tests a new drug called SYS6055 in about 86 adults whose B-cell blood cancers have come back or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors or control the di…

This study tests a new combination of chemotherapy drugs before a cord blood transplant in 44 patients aged 60-69 with blood cancers. The goal is to see if this approach lowers the risk of death from transplant complications within 180 days. Participants receive the transplant an…

This early-phase study tests a new treatment using donor immune cells (γδT cells) that are engineered to target and destroy faulty B cells in people with severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and find the right dose in 9 adults wh…

This early-phase study tests a new treatment called IASO206 for people with a severe type of autoimmune hemolytic anemia that hasn't responded to standard therapies. The treatment uses a special type of cell therapy (in vivo CAR-T) to target and destroy faulty immune cells that a…

This study tests a new treatment for adults with a rare leukemia called acute leukemia of ambiguous lineage (ALAL). The treatment combines targeted drugs (blinatumomab, venetoclax, and possibly TKI drugs) with standard chemotherapy. The goal is to see if this approach improves su…

This study tests a drug called gecacitinib in 33 adults who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant and whose condition did not improve with steroids. The goal is to see if the drug can safely control the disease and reduce symptoms. Participan…

This early study tests a new treatment called IASO206 for people with multiple myeloma that has come back or stopped responding to other therapies. The treatment uses a special type of cell therapy that works inside the body to attack cancer cells. The main goals are to check if …

This study tests a milder chemotherapy combination (thiotepa and melphalan) given before a stem cell transplant for people with blast phase chronic myeloid leukemia, an advanced and hard-to-treat form of the disease. The goal is to improve survival while reducing serious side eff…

This early-phase study tests a new treatment called LVIVO-TaVec400 for people with multiple myeloma that has returned or not responded to standard therapies. About 38 adults will receive the therapy to see if it is safe and to find the best dose. The treatment uses specially modi…

This study tests a new treatment called KL003 for people with severe sickle cell disease. The treatment uses a patient's own blood stem cells, modified with a healthy gene, to help produce normal red blood cells. Three participants aged 12 to 50 will receive a single infusion. Th…

This study tests whether a combination of two drugs (olverembatinib and inotuzumab ozogamicin) can clear remaining leukemia cells in adults with a specific type of acute lymphoblastic leukemia (Ph+ ALL) who still have detectable disease after initial treatment. The goal is to ach…

This early-stage study tests a new drug called CT1390B in 18 adults aged 18-70 with acute myeloid leukemia that has come back or not responded to standard treatment. The main goals are to check safety, find the right dose, and see if the drug can shrink the cancer. Participants m…

This early-phase trial tests a new approach for people with relapsed or refractory acute myeloid leukemia (AML). Ten participants will receive a sequence of two types of CAR-T cells designed to target leukemia cells, followed by a stem cell transplant. The main goal is to check s…

This study tests whether giving focused radiation (SBRT) to tumors outside the bone marrow before a donor stem cell transplant can improve survival and reduce cancer return in adults with blood cancers. About 20 participants aged 18-60 will be enrolled. The goal is to see if this…

This study tests a combination of targeted therapy (zanubrutinib) and reduced-dose chemotherapy for people with untreated Waldenström macroglobulinemia, a rare blood cancer. About 43 participants will receive four cycles of the combo, then eight months of zanubrutinib alone. The …

This early-phase study tests a treatment called GC012F for people with difficult-to-treat rheumatoid arthritis. The goal is to see if it is safe and how long the modified immune cells stay in the body. Only 9 adults aged 18 to 75 will take part. This is not a cure, but aims to co…

This early-phase trial tests whether giving a bispecific antibody drug before CAR-T cell therapy can improve outcomes for people with relapsed/refractory multiple myeloma, a blood cancer that has stopped responding to standard treatments. About 20 adults will receive the antibody…

This early-phase study tests a new treatment called CY-219 CAR-T cells for people with B-cell lymphoma that has come back or not responded to standard therapy. The treatment involves modifying the patient's own immune cells to better recognize and attack cancer cells. The main go…

This study tests a drug called CM336 (a BCMA/CD3 bispecific antibody) as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. The goal is to see if it can turn patients from MRD-positive (having minimal residual disease) to MRD-negativ…

This early-stage study tests a new treatment called CT1195E CAR-T cells for people with certain blood cancers (B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia) that have returned or not responded to standard therapy. The main goals are to check the treatment's …

This early-phase study tests whether giving a bispecific antibody (CM336) before CAR-T cell therapy can improve outcomes for people with relapsed or refractory multiple myeloma. Ten participants will receive the antibody as a "bridge" to control the cancer before the main CAR-T i…

This study tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) as a first treatment for people with follicular lymphoma, a slow-growing blood cancer. The goal is to see how well the drugs shrink or eliminate tumors and to check for side effects. Abou…

This early-phase study tests a new type of CAR-T cell therapy (CD19X) in 3 people with large B-cell lymphoma that has returned or not responded to standard treatment. The main goal is to check safety, looking for side effects like immune reactions or nerve problems. Researchers w…

This study tests whether adding venetoclax to azacitidine as maintenance therapy helps prevent relapse in people with acute myeloid leukemia (AML) who are already in remission after initial treatment. About 788 participants aged 14 to 74 will be randomly assigned to receive eithe…

This study tests a combination of two drugs, pomalidomide and obinutuzumab, in people with slow-growing lymphomas (like follicular lymphoma) that have not responded to or returned after previous treatment. The first part finds the safest dose, and the second part checks how well …

This study tests if the drug luspatercept can improve anemia in 20 adults with blood cancers who have had a stem cell transplant. The main goal is to see if it reduces the need for red blood cell transfusions. Participants will receive the drug and be monitored for side effects a…

This early-phase study tests a new treatment called IASO104 for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main…

This study tests a new drug called zuberitamab for people who develop Epstein-Barr virus (EBV) infection after a stem cell transplant. EBV can cause a serious condition called PTLD, which can be deadly if not treated. The drug targets a protein on infected cells to help clear the…

This early-stage study tests a new type of CAR-T cell therapy (Sup19) in 9 adults with B-cell leukemia or lymphoma whose cancer either stopped responding to prior CD19-targeted treatments or has weak CD19 markers. The main goal is to check safety and find the right dose, while al…

This study tests two drugs, mosunetuzumab and zeprumetostat, together for people with follicular lymphoma, a type of blood cancer. About 80 adults will join, including those newly diagnosed and those whose cancer returned. The goal is to see if the combination can shrink tumors a…

This study tests a new treatment called CD19 UCAR-T cells for people with autoimmune diseases like lupus, vasculitis, and Sjögren's syndrome. The goal is to see if it is safe and can control the disease. About 24 adults aged 18 to 65 will take part. The treatment uses modified im…

This study compares two first-line treatments for severe aplastic anemia (SAA) in patients without a fully matched donor: a half-matched stem cell transplant (from a family member) versus strong immune-suppressing drugs. About 116 people aged 14-70 will be followed to see which a…

This early-phase study tests a fixed-duration combination of ibrutinib, bendamustine, and rituximab in 21 adults with Waldenström macroglobulinemia, a rare blood cancer. The goal is to find the safest dose and see if a short treatment course can control the disease without lifelo…

This early-phase trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for adults with newly diagnosed acute myeloid leukemia (AML). The goal is to see if this mix is safe and improves remission rates. About 30 partici…

This study aims to reduce CMV infections in stem cell transplant patients by using a scoring system that measures immune recovery. The system helps doctors decide when to stop antiviral medication (letermovir) safely. Over 1,100 participants will be enrolled to see if this approa…

This study tests whether adding all-trans retinoic acid (ATRA) to the standard drug avatrombopag helps adults with immune thrombocytopenia (ITP) maintain safe platelet levels after stopping treatment. About 248 people whose ITP did not improve with first therapy or came back will…

This early-phase trial tests a new treatment called CD7 CAR-T cell therapy for 10 children with high-risk T-cell leukemia or lymphoma. After initial chemotherapy puts the cancer into remission, the child's own immune cells are collected, engineered to target cancer cells, and giv…

This study tests whether the drug gecacitinib, given before, during, and after a stem cell transplant, can help people with myelofibrosis (a rare bone marrow cancer) live longer without serious complications like graft-versus-host disease or relapse. About 39 adults aged 18-75 wi…

This study looks at 112 people with immune thrombocytopenia (ITP) whose platelet counts didn't improve after standard treatment with rhTPO. After a two-week break, half will get a higher dose of rhTPO and half will switch to a different drug called eltrombopag. The goal is to see…

This study tests whether giving the drug ruxolitinib early can prevent severe graft-versus-host disease (GvHD) in adults receiving a stem cell transplant from a half-matched donor. The trial uses a special model (daGOAT) to identify patients at highest risk. About 438 participant…

This early study tests whether probiotics made from a patient's own or their donor's gut bacteria can improve intestinal health in people who develop acute graft-versus-host disease (aGVHD) after a stem cell transplant. Ten adults over age 50 will take the probiotic capsules and …

This early-stage study tests a new drug called QI-019B in 24 adults with multiple myeloma that has returned or not responded to at least two prior treatments. The main goal is to check safety and find the right dose, while also seeing if it helps control the cancer. This is not a…

This study tests whether metformin, a common diabetes drug, can reduce harmful DNMT3A gene mutations in 30 adults with acute leukemia who are in remission. Participants take metformin pills for 6 months. The goal is to see if the drug lowers mutation levels and helps prevent the …

This early-phase trial tests a new treatment called JY509 universal NK cell injection for children whose B-cell acute lymphoblastic leukemia has returned or not responded to standard therapy. About 18 children will receive the cells to see if it is safe and helps control the dise…

This study tests whether a three-drug combination (VAG) works better than standard chemotherapy for adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). About 300 people aged 14 to 74 will be randomly assigned to receive either the new triple-drug reg…

This early-phase study tests a new treatment called SL4903 for people with multiple myeloma that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better attack cancer cells. About 9 to 18 adults …

This study tests whether the drug ivarmacitinib can prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a stem cell transplant from a half-matched donor. aGVHD occurs when donor immune cells attack the patient's body. The study will measure h…

This study tests a new drug (JAK1 inhibitor) combined with strong immune-suppressing therapy for people with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The trial has two parts: first, a small safety test in patients who didn't …

This early-stage study tests a new treatment called CT1194D CAR-T cells for patients whose B-cell blood cancers have returned or not responded to standard therapy. The main goals are to check the treatment's safety and find the best dose. About 20 adults aged 18-75 will take part…

This study tests a drug called daratumumab in people with aplastic anemia that hasn't improved with standard treatments. The goal is to see if it is safe and can help the body make more blood cells. About 37 participants will receive multiple doses, and researchers will check for…

This study looks at whether Polyene Phosphatidylcholine injection can prevent or treat liver injury caused by chemotherapy in adults with blood cancers like leukemia or lymphoma. Researchers will review medical records of 1000 patients to see how well the drug works and if it is …

This study is for adults aged 14 to 60 with newly diagnosed Ph-negative acute lymphoblastic leukemia (ALL), a fast-growing blood cancer. Researchers are testing a treatment plan that combines a pediatric-style chemotherapy with the targeted drug venetoclax and immunotherapy. The …

This early-stage study is testing a new type of CAR-T cell therapy, called BAFF-R CAR-T, for people with B-cell lymphomas that have come back or haven't responded to other treatments. Researchers will give the therapy at different doses to about 20 participants to check how safe …

This early study tests whether specially trained immune cells from a donor can prevent Epstein-Barr virus (EBV) infection in people who have received a stem cell transplant. About 9 to 18 participants will receive the cells and be monitored for safety and effectiveness. The goal …

This study will look back at medical records of 500 people with immune thrombocytopenia (ITP) to see what treatments they received and how well they worked. It includes both treated and untreated patients aged 6 and older. The goal is to understand current treatment practices and…

This study looks at how the antifungal drug liposomal amphotericin B behaves in 10 critically ill adults with severe fungal infections who are also receiving plasma exchange therapy. The goal is to understand how plasma exchange affects drug levels, safety, and effectiveness, so …

This study aims to find proteins in the blood that can predict chronic graft-versus-host disease (cGVHD), a serious complication after stem cell transplants. Researchers will analyze blood samples from 1,500 transplant recipients to build a model that helps doctors diagnose cGVHD…

This study will follow 1,000 adults who have received a stem cell transplant to learn more about a type of drug-resistant bacteria called MBL-CRE. Researchers will check for the bacteria using swabs and track who gets infections, what risk factors are involved, and how the bacter…